DMIIR
Drugs Made In America Acquisition II Corp. RightKey Statistics
About Drugs Made In America Acquisition II Corp. Right
Drugs Made In America Acquisition II Corp. Right (DMIIR) is a special purpose acquisition company (SPAC) strategically focused on merging with innovative pharmaceutical firms dedicated to bolstering domestic drug manufacturing capabilities. Led by an experienced management team, DMIIR is positioned to address the growing demand for affordable and accessible medications within the U.S. healthcare landscape. The company seeks to execute targeted acquisitions that not only enhance shareholder value but also contribute to the strengthening of the essential healthcare infrastructure in America, ultimately fostering a more resilient and self-sufficient pharmaceutical ecosystem.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -812,113 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.32% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.28 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $50.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DMIIR and any ticker you trade — then tracks every position and per-strategy win rate.